Prot# COMB157G2302: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis

Project: Research project

Project Details

StatusFinished
Effective start/end date3/1/16 → 5/31/20

Funding

  • Novartis Pharmaceuticals Corporation (Prot# COMB157G2302)